💊
Nilotinib Accord
nilotinib
Leucemia mieloide crónica, BCR-ABL positiva
✅ Autorizado
Genérico
✅
No hay alertas activas
Este medicamento no tiene escasez en curso, cartas de seguridad ni retiradas del mercado.
Para qué se utiliza
Nilotinib Accord is indicated for the treatment of: - adult and paediatric patients with newly diagnosed Philadelphia chromosome positive chronic myelogenous leukaemia (CML) in the chronic phase, - adult patients with chronic phase and accelerated phase Philadelphia chromosome positive CML with resistance or intolerance to prior therapy including imatinib. Efficacy data in patients with CML in blast crisis are not available, - paediatric patients with chronic phase Philadelphia chromosome positive CML with resistance or intolerance to prior therapy including imatinib.
⚠️ Seguridad del paciente
No
Página oficial de la EMA
https://www.ema.europa.eu/en/medicines/human/EPAR/nilotinib-accord